Introduction:
The UK is rapidly increasing its presence in biologics manufacturing, with investments in capacity for manufacturing monoclonal antibodies, viral vectors, and mRNA therapies. The country has a growing start-up and scale-up biopharma ecosystem and has become a hub for manufacturing biomedicines. The UK government has recognized the importance of manufacturing medicines and has invested significant funds in capital grants for next-generation therapies. The UK also has expertise in protein analysis and has developed innovative analytical technologies to assess product quality in biologics manufacturing. These advancements position the UK as a key player in the biologics manufacturing industry.
- The UK is developing a start-up and scale-up biopharma ecosystem with investments in manufacturing capacity for monoclonal antibodies, viral vectors, and mRNA therapies.
- The UK government has recognized the importance of manufacturing medicines and has invested capital grants in next-generation therapies.
- The UK has expertise in protein analysis and has developed innovative analytical technologies to assess product quality in biologics manufacturing.
- New developments in protein analysis include Amperia, a benchtop instrument for at-line protein quantification, and SamuxMP, a mass photometer system for AAV analysis.
- Other advancements in biologics manufacturing include the use of dielectric spectroscopy for real-time monitoring of cell features and predicting cell behavior.
Conclusion:
The UK is boosting its presence at the biologics manufacturing table with investments in manufacturing capacity and advancements in protein analysis technology. These developments position the UK as a key player in the biologics manufacturing industry and offer opportunities for growth in the sector. With its growing start-up and scale-up biopharma ecosystem, the UK is well-positioned to contribute to the development and manufacturing of next-generation therapies.
